Sterile, quadrivalent, liquid vaccine comprises recombinant basic capsid (L1) protein of human papillomavirus (HPV) serotypes 6, 11, 16, 18 virus-like particles assembled into virus-like particles, which are then purified and adsorbed with an aluminium-containing adjuvant. The vaccine is recommended for prevention of cervical, vulvar and vaginal cancer, precancerous conditions and dysplasia, genital warts, persistent infection with human papillomavirus (HPV) types 6, 11, 16 and 18, protection against cervical dysplasia and AIS, and HPV types 31, 33, 52 and 58 (stage 1, 2, 3), and provides approximately 90% protection against papillomaviruses spread worldwide. Produced under license issued by Serum Institute of India Internationally accepted vaccination schedule:

• • For boys and girls 9-15 years old and for girls 16-26 years old:
  • Second dose: In 1-2 months after the first dose;
  • Third dose: In 4-6 months after the second dose,
  • Can be administered separately or at the same time (in another administration site and into the other limb) with hepatitis B vaccine, meningococcal vaccine, diphtheria vaccine, cell-free DPT and inactivated polio vaccine

Each acceptable 0.5 mL dose of the vaccine for humans for sterile intramuscular injection contains:

• • Approx. 20 µg L1 protein HPV 6, 40 µg L1 protein HPV 11, 40 µg L1 protein HPV 16 and 20 µg L1 protein HPV 18